GlassScriptPhysician profile
William J Dahms
NPI 1952419376
$94,089.56
in general payments reported to CMS, 2019-2025
38 companies · $2,656 in 2025
The $2,656 reported for 2025 was more than what 91% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $19K · 2020: $9,798 · 2021: $8,200 · 2022: $33K · 2023: $19K · 2024: $1,954 · 2025: $2,656.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $9,289 · Food and Beverage: $6,917 · Honoraria: $4,000 · Consulting Fee: $2,400 · Travel and Lodging: $1,196 · Education: $152.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $9,288.50 |
| Food and Beverage | $6,916.93 |
| Honoraria | $4,000.00 |
| Consulting Fee | $2,400.00 |
| Travel and Lodging | $1,196.21 |
| Education | $151.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vifor Pharma, INC. | $36,454.67 | 2019-2025 | Veltassa, Korsuva |
| Amgen INC. | $25,202.32 | 2019-2025 | Tavneos, Krystexxa, Parsabiv |
| Bayer Healthcare Pharmaceuticals INC. | $12,575.86 | 2021-2025 | |
| Fresenius USA Marketing, INC. | $9,044.57 | 2019-2025 | Korsuva, Velphoro, Velphoro |
| Horizon Therapeutics Plc | $3,163.54 | 2019-2023 | Krystexxa |
| Otsuka America Pharmaceutical, INC. | $2,613.77 | 2019-2025 | Jynarque, Voyxact |
| Mallinckrodt Hospital Products INC. | $981.33 | 2021-2025 | Acthar, Terlivaz |
| Astrazeneca Pharmaceuticals LP | $580.73 | 2019-2025 | Farxiga, Lokelma |
| Calliditas Therapeutics US INC. | $424.27 | 2022-2025 | Tarpeyo |
| Ardelyx, INC. | $349.28 | 2024-2025 | Ibsrela, Xphozah 30 Mg |
| Aurinia Pharma U.S., INC. | $324.10 | 2021-2025 | Lupkynis |
| Daiichi Sankyo INC. | $209.52 | 2019-2025 | Injectafer |
| Novartis Pharmaceuticals Corporation | $195.20 | 2024-2025 | |
| Travere Therapeutics, INC. | $191.97 | 2019-2025 | |
| Opko Pharmaceuticals, LLC | $190.15 | 2019-2025 | Rayaldee |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Akebia Therapeutics INC | $176.17 | 2021-2025 | Vafseo, Auryxia |
| Lilly USA, LLC | $164.18 | 2025 | Zepbound, Jardiance |
| Boston Scientific Corporation | $149.12 | 2020-2025 | Embold Fibered |
| Boehringer Ingelheim Pharmaceuticals, INC. | $144.82 | 2022-2025 | Jardiance |
| Kyowa Kirin, INC. | $114.83 | 2023-2025 | Crysvita |
| Ani Pharmaceuticals, INC. | $109.04 | 2025 | Purified Cortrophin Gel |
| Genzyme Corporation | $92.43 | 2019-2025 | |
| Medtronic, INC. | $84.79 | 2024 | Ellipsys Vascular Access System |
| Glaxosmithkline, LLC. | $76.18 | 2023-2024 | Benlysta, Jesduvroq |
| Alexion Pharmaceuticals, INC. | $65.88 | 2019-2024 | Ultomiris |
| Takeda Pharmaceuticals U.S.A., INC. | $64.68 | 2020-2025 | Gattex |
| Shield Therapeutics INC | $54.50 | 2024 | |
| Amag Pharmaceuticals, INC. | $43.35 | 2019 | |
| Nxstage Medical, INC. | $39.08 | 2019 | |
| Mallinckrodt Enterprises LLC | $34.25 | 2019 | |
| Shire North American Group INC | $33.81 | 2019 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $33.23 | 2025 | |
| Bard Peripheral Vascular, INC. | $25.09 | 2019 | |
| Genentech USA, INC. | $22.44 | 2019 | |
| Surmodics, INC. | $18.71 | 2024 | Pounce Venous Thrombectomy System, Sublime Microcatheter, 018, 200cm, Straight, Sublime 014 Rx Pta Balloon Dilatation Catheter |
| Novo Nordisk INC | $18.71 | 2025 | Wegovy |
| Alnylam Pharmaceuticals INC. | $12.83 | 2019 | |
| Daxor Corporation | $10.16 | 2023 | Bva-100 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Dahms listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.